Research

Energy balance

Finerenone has been associated with reduced cardiovascular mortality and total worsening HF events across all BMI levels, with greater benefits observed in patients with higher BMIs.

Finerenone may be a beneficial treatment option for reducing cardiovascular risks in patients with varying BMI levels.

StrongSupportsmedium confidence
Exploratory analyses of the nonsteroidal mineralocorticoid receptor antagonist finerenone has been associated with reduced cardiovascular mortality and total worsening HF events across all body mass index (BMI) levels, with greater benefits observed in patients with higher BMIs.
Thomaz Alexandre Costa et al. · Current Opinion in Cardiology · 2025

Why this rating

Based on exploratory analyses from clinical trials.

Source

Advances in the management of obesity and heart failure: latest evidence from clinical trials

Thomaz Alexandre Costa et al. · Current Opinion in Cardiology · 2025

DOI 10.1097/hco.0000000000001214

reviewCited 7×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →